StemRD, Inc. — Department of Defense SBIR Phase I: Regenerative cell therapy using adult mesenchymal stem cells (MSCs) offers great potential
StemRD, Inc. — SBIR Phase I award from Department of Defense.
- Amount
- $149,998
- Agency
- Department of Defense · Defense Health Program
- Program / Phase
- SBIR · Phase I
- Solicitation
- 2010.3
- NAICS
- —
- Place of performance
- CA
- Period
- 2011-03-01
Description
Regenerative cell therapy using adult mesenchymal stem cells (MSCs) offers great potential to therapeutic cartilage repair. However, the current MSC chondrogenesis method of using TGF-beta is inefficient and assumes fibrocartilage-like features and hyper